In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
|Articles|December 4, 2017
MCC Releases Portfolio-level Milestone and SUSAR Performance Metrics
Advertisement
The Metrics Champion Consortium’s (MCC) Vendor Oversight Work Group has published its first set of portfolio-level metrics in order to answer high-priority vendor performance questions that relate to achieving timeliness goals. Not only will the metrics report if milestones are achieved by certain dates, but MCC has also created four more performance metrics used to measure the timeliness of SUSAR reporting.
Read the full release
Advertisement
Related to this article
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
4
ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval
5